Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies
Life · 29.05.2026 · 16 (6) · 915
DOI: 10.3390/life16060915 ↗Kurz gefasst
Editorial in der Zeitschrift Life, online erschienen am 29.05.2026. Verfasst von Ioannis Katsaros und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as one of the most pressing public health challenges, affecting more than 30% of the global adult population and projected to exceed 55% prevalence by 2040 [...]
Autor:innen und Institutionen
- First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Ioannis Katsaros, Dimitrios Schizas
Zitieren
APA
Katsaros, I., & Schizas, D. (2026). Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies. Life, 16(6), 915. https://doi.org/10.3390/life16060915
Vancouver
Katsaros I, Schizas D. Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies. Life. 2026;16(6):915. doi:10.3390/life16060915
BibTeX
@article{Katsaros2026,
author = {Katsaros, Ioannis and Schizas, Dimitrios},
title = {Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies},
journal = {Life},
year = {2026},
volume = {16},
number = {6},
pages = {915},
doi = {10.3390/life16060915}
}
EUVIMED